Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype
Overview
- Phase
- Not Applicable
- Intervention
- responders
- Conditions
- Depression
- Sponsor
- Samsung Medical Center
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Antidepressant Response at 6 weeks
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to determine whether pharmacogenomic study of bioamine transporters and peripheral lymphatic biomarkers(phenotype) predict antidepressant responsiveness in advance before the appearance of the drug effects until 4~6 weeks after drug administration.
Detailed Description
The purpose of this study is to determine whether genomic effects or peripheral lymphatic biomarkers on antidepressant response differed by class of drug, whether genomic and biomarker differences between drug responders and nonresponders predict the response of antidepressant and to construct the prediction model for antidepressant treatment in order to aid to select the their genetically or endophenotypic matching drugs.
Investigators
Doh Kwan Kim
M.D., pHD
Samsung Medical Center
Eligibility Criteria
Inclusion Criteria
- •eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition.
- •interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians
Exclusion Criteria
- •received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
- •potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.
Arms & Interventions
responders
50 ≤ Decrease rate(%) of HAM-D score
Intervention: responders
non-responders
nonresponders is a patients having 50 \> Decrease rate(%) of HAM-D score
Intervention: non-responders
Outcomes
Primary Outcomes
Antidepressant Response at 6 weeks
Time Frame: 6 weeks
antidepressant response is defined as the decrease rate of HAM-D score for 6week was = or \> 50% Measurement Unit = responders, nonresponders
Secondary Outcomes
- Biological value at 0 and 6 weeks(6 weeks)